Targeting Acetyl-CoA carboxylases: Small molecular inhibitors and their therapeutic potential

Recent Patents on Anti-Cancer Drug Discovery

Volumn 7, Issue 2, 2012, Pages 168-184

  Luo, Di Xian ^a,b   Tong, Di Jun ^c   Rajput, Sandeep ^b   Wang, Chun ^d,e   Liao, Duan Fang ^d,e   Cao, Deliang ^b   Maser, Edmund ^f  

^a THE FIRST PEOPLE S HOSPITAL OF CHENZHOU   (China)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Central Hospital of Yiyang   (China)

^d UNIVERSITY OF SOUTH CHINA   (China)

^e HUNAN UNIVERSITY OF CHINESE MEDICINE   (China)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Acetyl CoA carboxylases; Cancer; Fatty acid synthesis; Inhibitors; Metabolic syndromes; Obesity

Indexed keywords

(4 PIPERIDINYL)PIPERAZINE; 3,3,14,14 TETRAMETHYLHEXADECANEDIOIC ACID; 4 [1 (4 TERTBUTYLPHENYL) 2 OXO 4 PYRROLIDINYL]METHOXYBENZOIC ACID; 5 TETRADECOXYFURAN 2 CARBOXYLIC ACID; 8 HYDROXY 2,2,14,14 TETRAMETHYLPENTADECANEDIOIC ACID; [1 [1 (ANTHRACENE 9 CARBONYL)PIPERIDIN 4 YL]PIPERIDIN 3 YL]MORPHOLIN 4 YLMETHANONE; ACETYL COENZYME A CARBOXYLASE INHIBITOR; ANDRIMID; ANTHRANILIC ACID DERIVATIVE; AVENACIOLIDE; BENZODIOXEPINE DERIVATIVE; BENZOIC ACID DERIVATIVE; BENZTHIAZOLYLAMIDE DERIVATIVE; BIOTIN CARBOXYLASE; BIOTIN DERIVATIVE; BIPIPERIDINYLCARBOXAMIDE DERIVATIVE; CARBOXYLASE; CARBOXYLTRANSFERASE; CP 640186; CURCUMIN DERIVATIVE; CYCLOHEXYL DERIVATIVE; ESP 55016; HALOXYFOP; LIGASE INHIBITOR; MORAIMIDE B; OMEGA HYDROXY ALKANEDICARBOXYLIC ACID; PSEUDOPEPTIDE PYRROLIDINE DIONE; SETHOXYDIM; SORAPHEN A; SULFONAMIDE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ATHEROSCLEROSIS; CANCER THERAPY; CRYSTAL STRUCTURE; DIABETES MELLITUS; DRUG CLASSIFICATION; DRUG POTENCY; DRUG RESEARCH; DRUG SYNTHESIS; DRUG TARGETING; DYSLIPIDEMIA; ENERGY METABOLISM; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME STRUCTURE; ENZYME SUBUNIT; FAMILIAL HYPERCHOLESTEROLEMIA; FATTY ACID SYNTHESIS; HUMAN; HYPERLIPIDEMIA; MALIGNANT NEOPLASTIC DISEASE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PATENT; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; SEQUENCE HOMOLOGY;

ACETYL-COA CARBOXYLASE; ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; BACTERIAL INFECTIONS; ENZYME INHIBITORS; FEMALE; HERBICIDES; HUMANS; METABOLIC DISEASES; MICE; MYCOSES; NEOPLASMS; OBESITY; PATENTS AS TOPIC; RATS;

EID: 84860284103     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489212799972918     Document Type: Review

References (176)

1. Mojiminiyi OA, Al Mulla FAbdella NA. Which obesity index best explains the link between adipokines, coronary heart disease risk and metabolic abnormalities in type 2 diabetes mellitus? Med Princ Pract 2009; 18: 123-9.
2. Rana JS, Nieuwdorp M, Jukema JW, Kastelein JJ. Cardiovascular metabolic syndrome-an interplay of, obesity, inflammation, diabetes and coronary heart disease. Diabetes Obes Metab 2007; 9: 218-32.
3. Wild SH, Byrne CD. ABC of obesity. Risk factors for diabetes and coronary heart disease. BMJ 2006; 333: 1009-11.
4. Plecka Ostlund M, Marsk R, Rasmussen F, Lagergren JNaslund E. Morbidity and mortality before and after bariatric surgery for morbid obesity compared with the general population. Br J Surg 2011; 98: 811-6.
5. Losina E, Walensky RP, Reichmann WM, Holt HL, Gerlovin H, Solomon DH, et al. Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans. Ann Intern Med 2011; 154: 217-26.
6. Reilly JJ, Kelly J. Long-term impact of overweight and obesity in childhood and adolescence on morbidity and premature mortality in adulthood: Systematic review. Int J Obes (Lond) 2011; 35: 891-8.
7. Moore F, Brophy PJ. Regulation of acetyl-CoA carboxylase (ACC) by ATP depletion in developing oligodendrocytes mimics the action of AMP-activated protein kinase (AMPK). Biochem Soc Trans 1994; 22: 416S.
8. Witters LA, Nordlund AC, Marshall L. Regulation of intracellular acetyl-CoA carboxylase by ATP depletors mimics the action of the 5'-AMP-activated protein kinase. Biochem Biophys Res Commun 1991; 181: 1486-92.
9. Rabinkov AG, Amontov SV, Buneva VN, Tarussova NB. Interaction of ATP with acetyl-CoA carboxylase from rat liver. The role of the polyphosphate chain. Affinity labelling with alkylating amides of ATP and ADP. Biochimie 1990; 72: 719-24.
10. Ohlrogge J, Browse J. Lipid biosynthesis. Plant Cell 1995; 7: 957-70.
11. Boone AN, Rodrigues B, Brownsey RW. Multiple-site phosphorylation of the 280kDa isoform of acetyl-CoA carboxylase in rat cardiac myocytes: Evidence that cAMP-dependent protein kinase mediates effects of beta-adrenergic stimulation. Biochem J 1999; 341 (Pt 2): 347-54.
12. Gurvitz A. Physiological function of mycobacterial mtFabD, an essential malonyl-CoA: AcpM transacylase of type 2 fatty acid synthase FASII, in yeast mct1Delta cells. Comp Funct Genomics 2009: 836172.
13. Arthur CJ, Williams C, Pottage K, Ploskon E, Findlow SC, Burston SG, et al. Structure and malonyl CoA-ACP transacylase binding of Streptomyces coelicolor fatty acid synthase acyl carrier protein. ACS Chem Biol 2009; 4: 625-36.
14. Huang YS, Ge J, Zhang HM, Lei JQ, Zhang XL, Wang HH. Purification and characterization of the Mycobacterium tuberculosis FabD2, a novel malonyl-CoA:AcpM transacylase of fatty acid synthase. Protein Expr Purif 2006; 45: 393-9.
15. Thupari JN, Pinn ML, Kuhajda FP. Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity. Biochem Biophys Res Commun 2001; 285: 217-23.
16. Ventura FV, Costa CG, IJlst L, Dorland L, Duran M, Jakobs C, et al. Broad specificity of carnitine palmitoyltransferase II towards long-chain acyl-CoA beta-oxidation intermediates and its practical approach to the synthesis of various long-chain acylcarnitines. J Inherit Metab Dis 1997; 20: 423-6.
17. Tong L, Harwood HJ, Jr. Acetyl-coenzyme A carboxylases: Versatile targets for drug discovery. J Cell Biochem 2006; 99: 1476-88.
18. Harwood HJ, Jr., Petras SF, Shelly LD, Zaccaro LM, Perry DA, Makowski MR, et al. Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals. J Biol Chem 2003; 278: 37099-111.
19. Beckers A, Organe S, Timmermans L, Scheys K, Peeters A, Brusselmans K, et al. Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res 2007; 67: 8180-7.
20. Diacovich L, Peiru S, Kurth D, Rodriguez E, Podesta F, Khosla C, et al. Kinetic and structural analysis of a new group of Acyl-CoA carboxylases found in Streptomyces coelicolor A3(2). J Biol Chem 2002; 277: 31228-36.
21. Rodriguez E, Banchio C, Diacovich L, Bibb MJ, Gramajo H. Role of an essential acyl coenzyme A carboxylase in the primary and secondary metabolism of Streptomyces coelicolor A3(2). Appl Environ Microbiol 2001; 67: 4166-76.
22. Rodriguez E, Gramajo H. Genetic and biochemical characterization of the alpha and beta components of a propionyl-CoA carboxylase complex of Streptomyces coelicolor A3(2). Microbiology 1999; 145 (Pt 11): 3109-19.
23. Chuakrut S, Arai H, Ishii M Igarashi Y. Characterization of a bifunctional archaeal acyl coenzyme A carboxylase. J Bacteriol 2003; 185: 938-47.
24. Kiatpapan P, Kobayashi H, Sakaguchi M, Ono H, Yamashita M, Kaneko Y, et al. Molecular characterization of Lactobacillus plantarum genes for beta-ketoacyl-acyl carrier protein synthase III (fabH) and acetyl coenzyme A carboxylase (accBCDA), which are essential for fatty acid biosynthesis. Appl Environ Microbiol 2001; 67: 426-33.
25. Zhang H, Yang Z, Shen Y, Tong L. Crystal structure of the carboxyltransferase domain of acetyl-coenzyme A carboxylase. Science 2003; 299: 2064-7.
26. Leibundgut M, Maier T, Jenni S, Ban N. The multienzyme architecture of eukaryotic fatty acid synthases. Curr Opin Struct Biol 2008; 18: 714-25.
27. Maier T, Leibundgut M, Ban N. The crystal structure of a mammalian fatty acid synthase. Science 2008; 321: 1315-22.
28. Artymiuk PJ, Poirrette AR, Rice DW, Willett P. Biotin carboxylase comes into the fold. Nat Struct Biol 1996; 3: 128-32.
29. Galperin MY, Koonin EV. A diverse superfamily of enzymes with ATP-dependent carboxylate-amine/thiol ligase activity. Protein Sci 1997; 6: 2639-43.
30. Thoden JB, Blanchard CZ, Holden HM, Waldrop GL. Movement of the biotin carboxylase B-domain as a result of ATP binding. J Biol Chem 2000; 275: 16183-90.
31. Waldrop GL, Rayment I, Holden HM. Three-dimensional structure of the biotin carboxylase subunit of acetyl-CoA carboxylase. Biochemistry 1994; 33: 10249-56.
32. Madauss KP, Burkhart WA, Consler TG, Cowan DJ, Gottschalk WK, Miller AB, et al. The human ACC2 CT-domain C-terminus is required for full functionality and has a novel twist. Acta Crystallogr D Biol Crystallogr 2009; 65: 449-61.
33. Bengtsson C, Blaho S, Saitton DB, Brickmann K, Broddefalk J, Davidsson O, et al. Design of small molecule inhibitors of acetyl-CoA carboxylase 1 and 2 showing reduction of hepatic malonyl-CoA levels in vivo in obese Zucker rats. Bioorg Med Chem 2011; 19: 3039-53.
34. Zhang H, Tweel B, Tong L. Molecular basis for the inhibition of the carboxyltransferase domain of acetyl-coenzyme-A carboxylase by haloxyfop and diclofop. Proc Natl Acad Sci USA 2004; 101: 5910-5.
35. Zhang H, Tweel B, Li J, Tong L. Crystal structure of the carboxyltransferase domain of acetyl-coenzyme A carboxylase in complex with CP-640186. Structure 2004; 12: 1683-91.
36. Tong, L., Zhang, H., Yang, Z. Carboxyltransferase domain of acetyl-CoA carboxylase. US7884189 (2011).
37. Fall RR, Vagelos PR. Acetyl coenzyme A carboxylase. Molecular forms and subunit composition of biotin carboxyl carrier protein. J Biol Chem 1972; 247: 8005-15.
38. Nenortas E, Beckett D. Purification and characterization of intact and truncated forms of the Escherichia coli biotin carboxyl carrier subunit of acetyl-CoA carboxylase. J Biol Chem 1996; 271: 7559-67.
39. Choi-Rhee E, Cronan JE. The biotin carboxylase-biotin carboxyl carrier protein complex of Escherichia coli acetyl-CoA carboxylase. J Biol Chem 2003; 278: 30806-12.
40. Swinnen JV, Ulrix W, Heyns W, Verhoeven G. Coordinate regulation of lipogenic gene expression by androgens: Evidence for a cascade mechanism involving sterol regulatory element binding proteins. Proc Natl Acad Sci USA 1997; 94: 12975-80.
41. Lopez JM, Bennett MK, Sanchez HB, Rosenfeld JM, Osborne TF. Sterol regulation of acetyl coenzyme A carboxylase: A mechanism for coordinate control of cellular lipid. Proc Natl Acad Sci USA 1996; 93: 1049-53.
42. Barber MC, Price NT, Travers MT. Structure and regulation of acetyl-CoA carboxylase genes of metazoa. Biochim Biophys Acta 2005; 1733: 1-28.
43. Liu QS, Pu L, Poo MM. Repeated cocaine exposure in vivo facilitates LTP induction in midbrain dopamine neurons. Nature 2005; 437: 1027-31.
44. Talukdar S, Hillgartner FB. The mechanism mediating the activation of acetyl-coenzyme A carboxylase-alpha gene transcription by the liver X receptor agonist T0-901317. J Lipid Res 2006; 47: 2451-61.
45. Hardie DG, Pan DA. Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochem Soc Trans 2002; 30: 1064-70.
46. Xiao CW, Wood C, Huang W, L'Abbe MR, Gilani GS, Cooke GM, et al. Tissue-specific regulation of acetyl-CoA carboxylase gene expression by dietary soya protein isolate in rats. Br J Nutr 2006; 95: 1048-54.
47. Cheng HL, Ji NJ, Peng YX, Shen X, Xu JH, Dong ZG, et al. Molecular characterization and tissue-specific expression of the acetyl-CoA carboxylase alpha gene from Grass carp, Ctenopharyngodon idella. Gene 2011; 487: 46-51.
48. Luo DX, Peng XH, Xiong Y, Liao DF, Cao D, Li L. Dual role of insulin-like growth factor-1 in acetyl-CoA carboxylase-alpha activity in human colon cancer cells HCT-8: Downregulating its expression and phosphorylation. Mol Cell Biochem 2011; 357: 255-62.
49. Li ZG, Yin WB, Song LY, Chen YH, Guan RZ, Wang JQ, et al. Genes encoding the biotin carboxylase subunit of acetyl-CoA carboxylase from Brassica napus and parental species: Cloning, expression patterns, and evolution. Genome 2011; 54: 202-11.
50. Shi X, Liu S, Metges CC, Seyfert HM. C/EBP-beta drives expression of the nutritionally regulated promoter IA of the acetyl-CoA carboxylase-alpha gene in cattle. Biochim Biophys Acta 2010; 1799: 561-7.
51. Li ZG, Yin WB, Guo H, Song LY, Chen YH, Guan RZ, et al. Genes encoding the alpha-carboxyltransferase subunit of acetyl-CoA carboxylase from Brassica napus and parental species: Cloning, expression patterns, and evolution. Genome 2010; 53: 360-70.
52. Chen XJ, Mao HL, Ma XM, Liu JX. Effects of dietary corn oil and vitamin E supplementation on fatty acid profiles and expression of acetyl CoA carboxylase and stearoyl-CoA desaturase gene in Hu sheep. Anim Sci J 2010; 81: 165-71.
53. Yao N, Lu CL, Zhao JJ, Xia HF, Sun DG, Shi XQ, et al. A network of miRNAs expressed in the ovary are regulated by FSH. Front Biosci 2009; 14: 3239-45.
54. Kim CW, Moon YA, Park SW, Cheng D, Kwon HJ, Horton JD. Induced polymerization of mammalian acetyl-CoA carboxylase by MIG12 provides a tertiary level of regulation of fatty acid synthesis. Proc Natl Acad Sci USA 2010; 107: 9626-31.
55. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005; 1: 15-25.
56. Kemp BE, Stapleton D, Campbell DJ, Chen ZP, Murthy S, Walter M, et al. AMP-activated protein kinase, super metabolic regulator. Biochem Soc Trans 2003; 31: 162-8.
57. Wong GW, Wang J, Hug C, Tsao TS, Lodish HF. A family of Acrp30/adiponectin structural and functional paralogs. Proc Natl Acad Sci USA 2004; 101: 10302-7.
58. Munday MR. Regulation of mammalian acetyl-CoA carboxylase. Biochem Soc Trans 2002; 30: 1059-64.
59. Magnard C, Bachelier R, Vincent A, Jaquinod M, Kieffer S, Lenoir GM, et al. BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains. Oncogene 2002; 21: 6729-39.
60. Shen Y, Tong L. Structural evidence for direct interactions between the BRCT domains of human BRCA1 and a phospho-peptide from human ACC1. Biochemistry 2008; 47: 5767-73.
61. Cao D, Fan ST, Chung SS. Identification and characterization of a novel human aldose reductase-like gene. J Biol Chem 1998; 273: 11429-35.
62. Zu X, Yan R, Robbins S, Krishack PA, Liao DF, Cao D. Reduced 293T cell susceptibility to acrolein due to aldose reductase-like-1 protein expression. Toxicol Sci 2007; 97: 562-8.
63. Yan R, Zu X, Ma J, Liu Z, Adeyanju M, Cao D. Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention. Int J Cancer 2007; 121: 2301-6.
64. Wang C, Yan R, Luo D, Watabe K, Liao DF, Cao D. Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls. J Biol Chem 2009; 284: 26742-8.
65. Ma J, Yan R, Zu X, Cheng JM, Rao K, Liao DF, et al. Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells. J Biol Chem 2008; 283: 3418-23.
66. Moreau K, Dizin E, Ray H, Luquain C, Lefai E, Foufelle F, et al. BRCA1 affects lipid synthesis through its interaction with acetyl-CoA carboxylase. J Biol Chem 2006; 281: 3172-81.
67. Grantham BD, Zammit VA. Binding of [14C]malonyl-CoA to rat liver mitochondria after blocking of the active site of carnitine palmitoyltransferase I. Displacement of low-affinity binding by palmitoyl-CoA. Biochem J 1986; 233: 589-93.
68. Harwood HJ, Jr. Treating the metabolic syndrome: Acetyl-CoA carboxylase inhibition. Expert Opin Ther Targets 2005; 9: 267-81.
69. Castelo-Branco PA, Rubinger MM, Alves Lde C, de Barros PM, Pereira SG, de Melo VJ, et al. Synthesis and antifungal activity of aromatic bis-gamma-lactones analogous to avenaciolide. Chem Biodivers 2007; 4: 2745-54.
70. Yu CM, Youn J, Jung J. Asymmetric sequential allylic transfer reaction for the synthesis of 2-(1-stannylvinyl)-1,3-diols: Concise synthesis of (-)-avenaciolide and (-)-isoavenaciolide. Angew Chem Int Ed Engl 2006; 45: 1553-6.
71. Castelo-Branco PA, Rubinger MM, Guilardi S, Leite VM, dos Santos AR, de Calves L, et al. Synthesis, characterization, absolute structural determination and antifungal activity of a new chlorinated aromatic avenaciolide analogue. Pest Manag Sci 2009; 65: 34-40.
72. Levert KL, Waldrop GL, Stephens JM. A biotin analog inhibits acetyl-CoA carboxylase activity and adipogenesis. J Biol Chem 2002; 277: 16347-50.
73. Gerth K, Pradella S, Perlova O, Beyer S, Muller R. Myxobacteria: Proficient producers of novel natural products with various biological activities--past and future biotechnological aspects with the focus on the genus Sorangium. J Biotechnol 2003; 106: 233-53.
74. Gerth K, Bedorf N, Irschik H, Hofle G, Reichenbach H. The soraphens: A family of novel antifungal compounds from Sorangium cellulosum (Myxobacteria). I. Soraphen A1 alpha: Fermentation, isolation, biological properties. J Antibiot (Tokyo) 1994; 47: 23-31.
75. Anderson, R., Hokama, T., Lee, S., Oey, R., Elich, T., Breazeale, S. Modulators of acetyl-coenzyme A carboxylase and methods of use thereof. US20080200461 (2008).
76. Srtrongin, R.M., Saraiva, M.C., Waldrop, G.L., Amspacher, D.R. Derivatized biotin compounds and methods of use. US6242610 (2001).
77. Waldrop, G.L., Stephens, J.M., Levert, K.L. Inhibition of the carboxyltransferase component of acetyl-CoA carboxylase, and the use of such inhibition in anti-cancer and anti-lipogenic therapies. US6485941(2002).
78. Brunner, N., Freiberg, C., Lampe, T., Newton, B., Otteneder, M., Pernerstorfer, J., Pohlmann, J., Schiffer, G., Shimada, M. Derivatives of andrimide and moiramide B having antibacterial properties. US7544709 (2009).
79. Brunner, N., Freiberg, C., Lampe, T., Newton, B., Otteneder, M., Pernerstorfer, J., Pohlmann, J., Schiffer, G., Shimada, M. Derivatives of andrimide and moiramide b having antibacterial properties. US20050080129 (2005).
80. Wellen, C.W. Use of curcumin and analogues thereof as inhibitors of ACC2. US20050267221 (2005).
81. Lee YK, Park SY, Kim YM, Park OJ. Regulatory effect of the AMPK-COX-2 signaling pathway in curcumin-induced apoptosis in HT-29 colon cancer cells. Ann N Y Acad Sci 2009; 1171: 489-94.
82. Kim T, Davis J, Zhang AJ, He X, Mathews ST. Curcumin activates AMPK and suppresses gluconeogenic gene expression in hepatoma cells. Biochem Biophys Res Commun 2009; 388: 377-82.
83. Pan W, Yang H, Cao C, Song X, Wallin B, Kivlin R, et al. AMPK mediates curcumin-induced cell death in CaOV3 ovarian cancer cells. Oncol Rep 2008; 20: 1553-9.
84. Naito J, Sasaki E, Ohta Y, Shinohara R, Ishiguro I. Anthranilic acid metabolism in the isolated perfused rat liver: Detection and determination of anthranilic acid and its related substances using high-performance liquid chromatography with electrochemical detection. Biochem Pharmacol 1984; 33: 3195-200.
85. Braun K, Gibson DT. Anaerobic degradation of 2-aminobenzoate (anthranilic acid) by denitrifying bacteria. Appl Environ Microbiol 1984; 48: 102-7.
86. Ikawa, H.M., Nishimura, K., Okada, T., Nakamura, N., Inaba, K., Kojima, H., Kosono, H. Hypoglycemic agent. US20030191323 (2003).
87. Gobbi, L.C., Gubler, M., Neidhart, W., Nettekoven, M.H. Benzodioxepine derivatives. US7459480 (2008).
88. Clark RF, Zhang T, Wang X, Wang R, Zhang X, Camp HS, et al. Phenoxy thiazole derivatives as potent and selective acetyl-CoA carboxylase 2 inhibitors: Modulation of isozyme selectivity by incorporation of phenyl ring substituents. Bioorg Med Chem Lett 2007; 17: 1961-5.
89. Gu YG, Weitzberg M, Clark RF, Xu X, Li Q, Zhang T, et al. Synthesis and structure-activity relationships of N-{3-[2-(4-alkoxyphenoxy)thiazol-5-yl]-1-methylprop-2-ynyl}carboxy derivatives as selective acetyl-CoA carboxylase 2 inhibitors. J Med Chem 2006; 49: 3770-3.
90. Clark RF, Zhang T, Xin Z, Liu G, Wang Y, Hansen TM, et al. Structure-activity relationships for a novel series of thiazolyl phenyl ether derivatives exhibiting potent and selective acetyl-CoA carboxylase 2 inhibitory activity. Bioorg Med Chem Lett 2006; 16: 6078-81.
91. Xu X, Weitzberg M, Keyes RF, Li Q, Wang R, Wang X, et al. The synthesis and structure-activity relationship studies of selective acetyl-CoA carboxylase inhibitors containing 4-(thiazol-5-yl)but-3-yn-2-amino motif: Polar region modifications. Bioorg Med Chem Lett 2007; 17: 1803-7.
92. Gu YG, Weitzberg M, Clark RF, Xu X, Li Q, Lubbers NL, et al. N-{3-[2-(4-Alkoxyphenoxy)thiazol-5-yl]-1-methylprop-2-ynyl}carboxy derivatives as acetyl-coA carboxylase inhibitors--improvement of cardiovascular and neurological liabilities via structural modifications. J Med Chem 2007; 50: 1078-82.
93. Henderson, S.T. Inhibitors of acetyl-CoA carboxylase for treatment of neuronal hypometabolism. US20110003767 (2011).
94. Dang, Q., Gibson, T.S., Jiang, H., Chuang, D.M., Bao, J., Jiang, J., Kassick, A., Ketec, A., Lan, P., Lu, H., Makara, G.M., Romero, A.F., Sebhat, I., Wilson, D., Wodka, D., Bookser, B.C. Novel cyclic benzimidazole derivatives useful as anti-diabetic agents. US20110263533 (2011).
95. Ohmori K, Yamada H, Yasuda A, Yamamoto A, Matsuura N, Kiniwa M. Anti-hyperlipidemic action of a newly synthesized benzoic acid derivative, S-2E. Eur J Pharmacol 2003; 471: 69-76.
96. Ohmori K, Yamada H, Yasuda A, Yamamoto A, Matsuura N, Kiniwa M. Effects of a novel antihyperlipidemic agent, S-2E, on the blood lipid abnormalities in homozygous WHHL rabbits. Metabolism 2004; 53: 680-5.
97. Ohmori K, Yamada H, Yasuda A, Yamamoto A, Matsuura N, Kiniwa M. Effects of a novel anti-hyperlipidemic agent, S-2E, on blood lipid levels in rats with fructose-induced hypertriglyceridemia. Pharmacology 2004; 72: 240-6.
98. Zuther E, Johnson JJ, Haselkorn R, McLeod R, Gornicki P. Growth of Toxoplasma gondii is inhibited by aryloxyphenoxypropionate herbicides targeting acetyl-CoA carboxylase. Proc Natl Acad Sci USA 1999; 96: 13387-92.
99. Alban C, Job D, Douce R. Biotin metabolism in plants. Annu Rev Plant Physiol Plant Mol Biol 2000; 51: 17-47.
100. Nikolau BJ, Ohlrogge JB, Wurtele ES. Plant biotin-containing carboxylases. Arch Biochem Biophys 2003; 414: 211-22.
101. Brunner, H. Cyclohexenonecarboxylic acid derivatives with herbicidal and plant growth regulating properties. US4640706 (1987).
102. Munger, J., Bennett, B., Shenk, T., Rabinowitz, J. Treatment of viral infections by modulation of host cell metabolic pathways. US20090239830 (2009).
103. Fukatsu, K., Kamata, M., Yamashita, T., Endo, S. Nitrogencontaining heterocyclic compound. WO2007119833 (2007).
104. Chonan T, Oi T, Yamamoto D, Yashiro M, Wakasugi D, Tanaka H, et al. (4-Piperidinyl)-piperazine: A new platform for acetyl-CoA carboxylase inhibitors. Bioorg Med Chem Lett 2009; 19: 6645-8.
105. Perry, D.A., Harwood, H.J. ACC inhibitors. WO03072197 (2003).
106. Fukatsu, K., Kamata, M., Yamashita, T. Heterocyclic compound. EP2123652 (2009).
107. Corbett, J.W., Elliott, R.L., Bell, A. Spiroketone acetyl-CoA carboxylase inhibitors. WO08065508 (2008).
108. Iino, T., Jona, H., Kurihara, H., Nakamura, M., Niiyama, K., Shibata, J., Shimamura, T., Watanabe, H., Yamakawa, T., Yang, L. Spirochromanon derivatives. WO2008088692 (2008).
109. Iino, T., Jona, H., Shibata, J., Shimamura, T., Yamakawa, T., Yang, L. Substituted spirochromanone derivatives as ACC inhibitors. WO2008088688 (2008).
110. Corbett JW, Freeman-Cook KD, Elliott R, Vajdos F, Rajamohan F, Kohls D, et al. Discovery of small molecule isozyme non-specific inhibitors of mammalian acetyl-CoA carboxylase 1 and 2. Bioorg Med Chem Lett 2010; 20: 2383-8.
111. Duennenberger, M., Schellenbaum, M. Furan-2,5-dicarboxylic acid diamides. US3546255 (1970).
112. Waldrop, G.L., Stephens, J.M., Levert, K.L. Inhibition of the carboxyltransferase component of acetyl-CoA carboxylase, and the use of such inhibition in anti-cancer and anti-lipogenic therapies. US6485941(2002).
113. Yamakawa, T., Jona, H., Niiyama, K., Yamada, K., Lino, T., Ohkubo, M., Imamura, H., Shibata, J., Kusunoki, J., Yang, L. Spirochromanone derivatives as acetyl coenzyme A carboxylase (ACC) inhibitors. US7935712 (2011).
114. Jona, H., Shibata, Y., Yamakawa, T. Novel spirochromanone carboxylic acids. US20110077262 (2011).
115. Corbett, J.W., Elliott, R., Freeman-cook, K., Griffith, D.A., Philipion, D.P. Pyrazolospiroketone acetyl-CoA carboxylase inhibitors. US20110028390 (2011).
116. Ligon J, Hill S, Beck J, Zirkle R, Molnar I, Zawodny J, et al. Characterization of the biosynthetic gene cluster for the antifungal polyketide soraphen A from Sorangium cellulosum So ce26. Gene 2002; 285: 257-67.
117. Shen Y, Volrath SL, Weatherly SC, Elich TD, Tong L. A mechanism for the potent inhibition of eukaryotic acetyl-coenzyme A carboxylase by soraphen A, a macrocyclic polyketide natural product. Mol Cell 2004; 16: 881-91.
118. Tong L. Acetyl-coenzyme A carboxylase: Crucial metabolic enzyme and attractive target for drug discovery. Cell Mol Life Sci 2005; 62: 1784-803.
119. Vahlensieck HF, Pridzun L, Reichenbach H, Hinnen A. Identification of the yeast ACC1 gene product (acetyl-CoA carboxylase) as the target of the polyketide fungicide soraphen A. Curr Genet 1994; 25: 95-100.
120. Weatherly SC, Volrath SL, Elich TD. Expression and characterization of recombinant fungal acetyl-CoA carboxylase and isolation of a soraphen-binding domain. Biochem J 2004; 380: 105-10.
121. Belkebir A, De Paepe R, Tremolieres A, Aid F, Benhassaine-Kesri G. Sethoxydim affects lipid synthesis and acetyl-CoA carboxylase activity in soybean. J Exp Bot 2006; 57: 3553-62.
122. Halvorson DL, McCune SA. Inhibition of fatty acid synthesis in isolated adipocytes by 5-(tetradecyloxy)-2-furoic acid. Lipids 1984; 19: 851-6.
123. Otto DA, Chatzidakis C, Kasziba E, Cook GA. Reciprocal effects of 5-(tetradecyloxy)-2-furoic acid on fatty acid oxidation. Arch Biochem Biophys 1985; 242: 23-31.
124. Malewiak MI, Griglio S, Le Liepvre X. Relationship between lipogenesis, ketogenesis, and malonyl-CoA content in isolated hepatocytes from the obese Zucker rat adapted to a high-fat diet. Metabolism 1985; 34: 604-11.
125. Sola MM, Oliver FJ, Salto R, Gutierrez M, Vargas A. Citrate inhibition of rat-kidney cortex phosphofructokinase. Mol Cell Biochem 1994; 135: 123-8.
126. Wang C, Xu C, Sun M, Luo D, Liao DF, Cao D. Acetyl-CoA carboxylase-alpha inhibitor TOFA induces human cancer cell apoptosis. Biochem Biophys Res Commun 2009; 385: 302-6.
127. Zhou W, Simpson PJ, McFadden JM, Townsend CA, Medghalchi SM, Vadlamudi A, et al. Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells. Cancer Res 2003; 63: 7330-7.
128. Pizer ES, Thupari J, Han WF, Pinn ML, Chrest FJ, Frehywot GL, et al. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res 2000; 60: 213-8.
129. Zhou W, Han WF, Landree LE, Thupari JN, Pinn ML, Bililign T, et al. Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells. Cancer Res 2007; 67: 2964-71.
130. Liu X, Fortin PD, Walsh CT. Andrimid producers encode an acetyl-CoA carboxyltransferase subunit resistant to the action of the antibiotic. Proc Natl Acad Sci USA 2008; 105: 13321-6.
131. Pohlmann J, Lampe T, Shimada M, Nell PG, Pernerstorfer J, Svenstrup N, et al. Pyrrolidinedione derivatives as antibacterial agents with a novel mode of action. Bioorg Med Chem Lett 2005; 15: 1189-92.
132. Campbell JW, Cronan JE, Jr. Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. Annu Rev Microbiol 2001; 55: 305-32.
133. Freiberg C, Brunner NA, Schiffer G, Lampe T, Pohlmann J, Brands M, et al. Identification and characterization of the first class of potent bacterial acetyl-CoA carboxylase inhibitors with antibacterial activity. J Biol Chem 2004; 279: 26066-73.
134. Solbiati J, Chapman-Smith A, Cronan JE, Jr. Stabilization of the biotinoyl domain of Escherichia coli acetyl-CoA carboxylase by interactions between the attached biotin and the protruding "thumb" structure. J Biol Chem 2002; 277: 21604-9.
135. Cramer CT, Goetz B, Hopson KL, Fici GJ, Ackermann RM, Brown SC, et al. Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome. J Lipid Res 2004; 45: 1289-301.
136. Ohno T, Yano S, Yamada H, Shirasaka T, Yamamoto A, Kobayashi K, et al. Synthesis of the optical isomers of 4-[1-(4-tertbutylphenyl)-2-oxo-pyrrolidine-4-yl]methyloxybenzoic acid (S-2) and their biological evaluation as antilipidemic agent. Chem Pharm Bull (Tokyo) 1999; 47: 1549-54.
137. Berg IA, Ivanovskii RN. [Enzymes of the citramalate cycle in Rhodospirillum rubrum]. Mikrobiologiia 2009; 78: 22-31.
138. Jin M, Fischbach MA, Clardy J. A biosynthetic gene cluster for the acetyl-CoA carboxylase inhibitor andrimid. J Am Chem Soc 2006; 128: 10660-1.
139. Zhao L, Chen YX, Varghese Z, Huang AL, Tang RK, Jia B, et al. Murine gamma herpes virus 68 infection promotes fatty liver formation and hepatic insulin resistance in C57BL/6J mice. Hepatol Int 2011 [Epub ahead of print].
140. Sirtori CR, Galli C, Franceschini G. Fraudulent (and non fraudulent) fatty acids for human health. Eur J Clin Invest 1993; 23: 686-9.
141. Yamashita, T., Kamata, M., Hirose, H., Murakami, M., Fujimoto, T., Ikeda, Z., Yasuma, T., Fujimori, I., Mizojiri, R., Yukawa, T. Bicyclic compound. US20110263562 (2011).
142. McCune SA, Harris RA. Mechanism responsible for 5-(tetradecyloxy)-2-furoic acid inhibition of hepatic lipogenesis. J Biol Chem 1979; 254: 10095-101.
143. Parker RA, Kariya T, Grisar JM, Petrow V. 5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids. J Med Chem 1977; 20: 781-91.
144. Bar-Tana J, Ben-Shoshan S, Blum J, Migron Y, Hertz R, Pill J, et al. Synthesis and hypolipidemic and antidiabetogenic activities of beta, beta, beta', beta'-tetrasubstituted, long-chain dioic acids. J Med Chem 1989; 32: 2072-84.
145. Tzur R, Rose-Kahn G, Adler JH, Bar-Tana J. Hypolipidemic, antiobesity, and hypoglycemic-hypoinsulinemic effects of beta, beta'-methyl-substituted hexadecanedioic acid in sand rats. Diabetes 1988; 37: 1618-24.
146. Russell JC, Amy RM, Graham SE, Dolphin PJ, Wood GO, Bar-Tana J. Inhibition of atherosclerosis and myocardial lesions in the JCR:LA-cp rat by beta, beta'-tetramethylhexadecanedioic acid (MEDICA 16). Arterioscler Thromb Vasc Biol 1995; 15: 918-23.
147. Berge RK, Skorve J, Tronstad KJ, Berge K, Gudbrandsen OA, Grav H. Metabolic effects of thia fatty acids. Curr Opin Lipidol 2002; 13: 295-304.
148. Skrede S, Sorensen HN, Larsen LN, Steineger HH, Hovik K, Spydevold OS, et al. Thia fatty acids, metabolism and metabolic effects. Biochim Biophys Acta 1997; 1344: 115-31.
149. Bremer J. The biochemistry of hypo-and hyperlipidemic fatty acid derivatives: Metabolism and metabolic effects. Prog Lipid Res 2001; 40: 231-68.
150. Menendez JA, Colomer R, Lupu R. Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids? Med Hypotheses 2005; 64: 342-9.
151. Chajes V, Lanson M, Fetissof F, Lhuillery C, Bougnoux P. Membrane fatty acids of breast carcinoma: Contribution of host fatty acids and tumor properties. Int J Cancer 1995; 63: 169-75.
152. Abramson HN. The lipogenesis pathway as a cancer target. J Med Chem 2011; 54: 5615-38.
153. Wang C, Rajput S, Watabe K, Liao DF, Cao D. Acetyl-CoA carboxylase-a as a novel target for cancer therapy. Front Biosci (Schol Ed) 2010; 2: 515-26.
154. Chajes V, Cambot M, Moreau K, Lenoir GM, Joulin V. Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival. Cancer Res 2006; 66: 5287-94.
155. Brusselmans K, De Schrijver E, Verhoeven G, Swinnen JV. RNA interference-mediated silencing of the acetyl-CoA-carboxylasealpha gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res 2005; 65: 6719-25.
156. Sinilnikova OM, Ginolhac SM, Magnard C, Leone M, Anczukow O, Hughes D, et al. Acetyl-CoA carboxylase alpha gene and breast cancer susceptibility. Carcinogenesis 2004; 25: 2417-24.
157. Guseva NV, Rokhlin OW, Glover RA, Cohen MB. TOFA (5-Tetradecyl-oxy-2-furoic acid) reduces fatty acid synthesis, inhibits expression of AR, neuropilin-1 and Mcl-1 and kills prostate cancer cells independent of p53 status. Cancer Biol Ther 2011; 12: 80-5.
158. Jump DB, Torres-Gonzalez M, Olson LK. Soraphen A, an inhibitor of acetyl CoA carboxylase activity, interferes with fatty acid elongation. Biochem Pharmacol 2011; 81: 649-60.
159. Abu-Elheiga L, Matzuk MM, Kordari P, Oh W, Shaikenov T, Gu Z, et al. Mutant mice lacking acetyl-CoA carboxylase 1 are embryonically lethal. Proc Natl Acad Sci USA 2005; 102: 12011-6.
160. Olson DP, Pulinilkunnil T, Cline GW, Shulman GI, Lowell BB. Gene knockout of ACC2 has little effect on body weight, fat mass, or food intake. Proc Natl Acad Sci USA 2010; 107: 7598-603.
161. Abu-Elheiga L, Matzuk MM, Abo-Hashema KA, Wakil SJ. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science 2001; 291: 2613-6.
162. Abu-Elheiga L, Oh W, Kordari P, Wakil SJ. Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets. Proc Natl Acad Sci USA 2003; 100: 10207-12.
163. Oh W, Abu-Elheiga L, Kordari P, Gu Z, Shaikenov T, Chirala SS, et al. Glucose and fat metabolism in adipose tissue of acetyl-CoA carboxylase 2 knockout mice. Proc Natl Acad Sci USA 2005; 102: 1384-9.
164. Savage DB, Choi CS, Samuel VT, Liu ZX, Zhang D, Wang A, et al. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest 2006; 116: 817-24.
165. Zhang S, Kim KH. Essential role of acetyl-CoA carboxylase in the glucose-induced insulin secretion in a pancreatic beta-cell line. Cell Signal 1998; 10: 35-42.
166. Zhang S, Kim KH. Glucose activation of acetyl-CoA carboxylase in association with insulin secretion in a pancreatic beta-cell line. J Endocrinol 1995; 147: 33-41.
167. Chen J, Jeppesen PB, Nordentoft I, Hermansen K. Stevioside improves pancreatic beta-cell function during glucotoxicity via regulation of acetyl-CoA carboxylase. Am J Physiol Endocrinol Metab 2007; 292: E1906-16.
168. Lane MD, Hu Z, Cha SH, Dai Y, Wolfgang M, Sidhaye A. Role of malonyl-CoA in the hypothalamic control of food intake and energy expenditure. Biochem Soc Trans 2005; 33: 1063-7.
169. Lane MD, Wolfgang M, Cha SH, Dai Y. Regulation of food intake and energy expenditure by hypothalamic malonyl-CoA. Int J Obes (Lond) 2008; 32 Suppl 4: S49-54.
170. Cesquini M, Stoppa GR, Prada PO, Torsoni AS, Romanatto T, Souza A, et al. Citrate diminishes hypothalamic acetyl-CoA carboxylase phosphorylation and modulates satiety signals and hepatic mechanisms involved in glucose homeostasis in rats. Life Sci 2008; 82: 1262-71.
171. Wolfgang MJ, Cha SH, Sidhaye A, Chohnan S, Cline G, Shulman GI, et al. Regulation of hypothalamic malonyl-CoA by central glucose and leptin. Proc Natl Acad Sci USA 2007; 104: 19285-90.
172. Gao S, Kinzig KP, Aja S, Scott KA, Keung W, Kelly S, et al. Leptin activates hypothalamic acetyl-CoA carboxylase to inhibit food intake. Proc Natl Acad Sci USA 2007; 104: 17358-63.
173. Sambandam N, Lopaschuk GD. AMP-activated protein kinase (AMPK) control of fatty acid and glucose metabolism in the ischemic heart. Prog Lipid Res 2003; 42: 238-56.
174. Defossa, E., Keil, S., Dietrich, V., Stengelin, S., Herling, A., Haschke, G., Klabunde, T. (2-aryloxyacetylamino) phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments. US20120004167 (2012).
175. Keli, S., Defossa, E., Dietrich, V., Stengelin, S., Herling, A., Haschke, G., Klabunde, T. Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments. US20120004165 (2012).
176. Keil, S., Defossa, E., Dietrich, V., Stengelin, S., Herling, A., Haschke, G., Klabunde, T. Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament. US20120004166 (2012).